Editor’s Picks

BioWorld delivers actionable intelligence on the most innovative drug development science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld reports the breaking news & and provides key perspective & on hundreds of medicines in development, the companies behind those therapeutic candidates, the business development transactions that evolve the market, and the regulatory hurdles that both challenge and guard the process.

Daily news coverage includes:

  • Therapeutic product development from early to late stage
  • Strategic alliances, mergers and acquisitions
  • Corporate financings, both public and private
  • Biopharma company advancements and setbacks
  • Scientific milestones
  • Global regulatory updates
  • Profiles of new and drug development innovators
  • Big pharma’s growing involvement in biotech

In addition to original daily news reporting, BioWorld offers an extensive searchable database at www.BioWorld.com with two decades’ worth of biopharmaceutical news archives. This site is not only a great source for insightful, up-to-the-minute news coverage, but a veritable library of information, analysis and data on the developments of the industry as well. With a quick search, BioWorld subscribers have instant access to a wealth of biopharmaceutical market intelligence from around the globe.

BioWorld Insight Gain insights into which products are ahead or behind in a particular product space, the potential impact of new and pending regulatory rules and ideas for generating capital funding that is the lifeblood of the industry.

Behind-the-scenes analysis plus:

  • BioWorld Stock Report for U.S. publicly traded companies, listings for the London and Toronto stock exchanges, plus the 10 biggest acheivers and losers for the week.
  • Find out who is ahead in niche markets, new and pending regulation, and ideas for generating capital.
  • Insight examines business challenges & and potential solutions & that constantly face both industry giants and brand new start-ups.

Inside each issue gain exclusive charts and graphs to key biopharma metrics including:

  • Clinical trial updates organized by indication (cancer, diabetes, etc.), plus FDA actions
  • Details of collaborations by biotech and pharma companies
  • Deal modifications and manufacturing agreements
  • Public and private financing
  • Public offering performance by underwriters
  • FDA actions

BioWorld Asia provides critical updates on the business, financial, clinical, scientific and regulatory developments affecting the biopharma industry.

  • Timely coverage: trademark BioWorld analysis and perspective on licensing deals, M&A and financings
  • Untangle regulatory knots: articles that clarify the process in China and other key markets
  • Enhance partnering opportunities: by analyzing options and companies via BioWorld’s signature BioPeople and NewCo News features
  • Recognize deal trends: and various financing options available to fund R&D
  • Alleviate intellectual property concerns: with articles that highlight this hot-button topic